SCI selects six countries for full support: Uganda, Burkina Faso, Niger, Mali, Tanzania, and Zambia. The countries each propose a different implementation approach and management structure for their large-scale schistosomiasis control.[5]

The British Department for International Development awards SCI an additional £16.6 million over four and a half years (June 2014 to December 2018) to extend the program and expand it to an additional two countries.[1]

2014

Coverage

ACI reaches median coverage for schistosomiasis treatment at 69% in Malawi, 82% in Côte d'Ivoire, and 47% in Uganda.[7]

2014 – 2015

Coverage

SCI reports having delivered 3.1 million treatments in Côte d'Ivoire in the period.[1]

GiveWell estimates that programs supported by SCI can deworm a person for approximately US$1.26 based (including the estimated cost of SCI’s funding to country programs, SCI’s headquarters costs, cost of donated drugs, and local government involvement).[7]

2017

January

Good Ventures awards a grant of US$13,500,000 to SCI for general operating support, in recognition of its earning a “top charity” ranking from GiveWell in 2016.[10]

2017

GiveWell allocates 100% of its discretionary fund to the SCI in the fourth quarter of the year, totalling US$5.6 million.[11]

2018

"In Q4 2017, GiveWell allocated 100% of its discretionary fund to the SCI, totalling $5.6 million. It allocated a further $0.89 million to the SCI in Q1 2018, which was 30% of its discretionary fund for that period."[11]